Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Heart rate and cardiovascular mortality: the Framingham Study.Am Heart J. 1987; 113: 1489-1494
- on behalf of the BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.Lancet. 2008; 372: 817-821
- Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.Lancet. 2010; 376: 886-894
- Heart rate as a prognostic marker and therapeutic target in acute and chronic heart failure.Int J Cardiol. 2018; 253: 97-104
- Heart rate in patients with reduced ejection fraction: relationship between single time point measurement and mean heart rate on prolonged implantable cardioverter defibrillator monitoring.BMC Cardiovasc Disord. 2018; 18: 17
- Organizational model and reactions to alerts in remote monitoring of cardiac implantable electronic devices: a survey from the Home Monitoring Expert Alliance project.Clin Cardiol. 2019; 42: 76-83
- Elevated heart rate: a major risk factor for cardiovascular disease.Clin Exp Hypertens. 2004; 26: 637-644
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.J Am Coll Cardiol. 2022; 79: e263-e421
- Resting heart rate as a predictive risk factor for sudden death in middle-aged men.Cardiovasc Res. 2001; 50: 373-378
- for the Heart Rate Working Group. Resting heart rate in cardiovascular disease.J Am Coll Cardiol. 2007; 50: 823-830
- Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program.J Am Coll Cardiol. 2012; 59: 1785-1795
- Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program.Eur Heart J. 2015; 36: 669-675
- Heart rate predicts outcomes in an implantable cardioverter-defibrillator population.Circulation. 2009; 120: 2040-2045
- Patient activity and survival following implantable cardioverter-defibrillator implantation: the ALTITUDE activity study.J Am Heart Assoc. 2015; 4e001775
- Association of implantable device measured physical activity with hospitalization for heart failure.JACC Heart Fail. 2020; 8: 280-288
- Combining home monitoring temporal trends from implanted defibrillators and baseline patient risk profile to predict heart failure hospitalizations: results from the SELENE HF study.Europace. 2022; 24: 234-244
- Relation between resting heart rate and the risk of ventricular tachyarrhythmias in MADIT-RIT.Europace. 2020; 22: 281-287
- Novel insights into the role of the sympathetic nervous system in cardiac arrhythmogenesis.Heart Rhythm. 2010; 7: 1900-1906
- Survival after implantable cardioverter-defibrillator shocks.J Am Coll Cardiol. 2021; 77: 2453-2462
- Influence of “high” defibrillation thresholds on patient survival and impact of system modification.J Cardiovasc Electrophysiol. 2022; 33: 234-240
- Lower rate limit for pacing by cardiac resynchronization defibrillators: should lower rate programming be reconsidered?.Heart Rhythm. 2021; 18: 2087-2093
- The role of atrial sensing for new-onset atrial arrhythmias diagnosis and management in single-chamber implantable cardioverter-defibrillator recipients: results from the THINGS registry.J Cardiovasc Electrophysiol. 2020; 31: 846-853
- Less is more: can we achieve cardiac resynchronization with 2 leads only?.Int J Cardiol. 2017; 249: 184-190
- Rate-responsive pacing and atrial high rate episodes in cardiac resynchronization therapy patients: is low heart rate the key?.Clin Cardiol. 2019; 42: 820-828
Publication stageIn Press Journal Pre-Proof
Funding Sources: Manuscript editing was partially supported by Biotronik Italia S.p.A. (Via Alessandro Volta 16, 20093, Cologno Monzese (MI), Italy). No other funds have been received to support this work.
Disclosures: Mr Giacopelli and Mr Gargaro are employees of Biotronik Italia.